Viking Therapeutics Inc【VKTX】株式ニュース

Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesMay 13, 2026 9:00 AM
InvestorsHub NewsWireNext-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market OpportunitiesBioMedWire Editorial Coverage: Obesity and type 2 diabetes mellitus ("T2DM") rank among the most urgent and costly healthcare problems facing the world today, contributing to surging rates of cardiovascular disease, fatty liver disease, kidney complications and ballooning healthcare expenses. What once represented a specialized class of diabetes treatments has grown into one of the most consequential therapeutic categories in modern medicine, with GLP-1 receptor agonists now fundamentally restructuring how obesity, metabolic disease and potentially even neurodegeneration are treated. Operating in this environment is SureNano Science Ltd. (CSE: SURE) (OTCQB: SURNF) (Profile), which through its subsidiary GlucaPharm Inc. is developing a distinct next-generation GLP-1 platform built around GEP-44, a novel triple agonist peptide engineered to improve efficacy, tolerability, and delivery flexibility within one of the most commercially dynamic pharmaceutical markets in history. SureNano is one of the emerging microcap companies active in the GLP-1 space, operating alongside established leaders including Merck & Co. Inc. (NYSE: MRK), AbbVie Inc. (NYSE: ABBV), Viking Therapeutics Inc. (NASDAQ: VKTX) and Altimmune Inc. (NASDAQ: ALT).SureNano Science is developing GEP-44 as a patented next-generation metabolic therapy designed to address the limitations of first-generation GLP-1 drugs.The commercial potential tied to GLP-1 therapies is expanding quickly, with the global GLP-1 market forecast to potentially reach $190 billion by 2035.SureNano Science is also eyeing differentiated drug-delivery technologies designed to improve patient accessibility and long-term adherence.Preclinical data from SureNano Science suggest that GEP-44 may offer substantive differentiation relative to earlier-generation GLP therapies.Beyond its primary GLP-1 metabolic platform, SureNano Science is also evaluating early-stage opportunities that could expand the long-term scope of its therapeutic and delivery technology portfolio.Click here to view the custom infographic of the SureNano Science editorial. Rewriting the Rules of Metabolic MedicineThe global obesity crisis shows no sign of plateauing. According to the World Health Organization ("WHO"), a reported one billion people globally are currently living with obesity, while type 2 diabetes rates continue to climb across both high-income and developing economies. The WHO further notes that obesity increases the risk of cardiovascular disease, stroke and T2DM, while further research has linked obesity to chronic kidney disease and rising healthcare expenditures, placing substantial and growing pressure on health systems around the world.GLP-1 receptor agonists have rapidly risen to become one of the defining breakthroughs in metabolic medicine. Originally introduced to manage blood glucose levels in diabetes patients, these drugs are now recognized for their capacity to drive meaningful weight reduction and deliver broad improvements in metabolic health. Market leaders Novo Nordisk A/S and Eli Lilly and Company have come to dominate the space through their blockbuster injectable franchises, including Ozempic(R), Wegovy(R), Mounjaro(R) and Zepbound(R).Commercial momentum in this space is increasing. JPMorgan Chase & Co. forecasts that the general obesity drug market could reach $200 billion by 2030 as global adoption expands and indications stretch beyond diabetes and weight management. Additional industry projections suggest GLP-1 therapies are on track to become one of the most commercially successful drug categories ever, with annual sales projections of $150 billion or more by the end of the decade.The industry is already pivoting toward the next generation of incretin therapies, with a focus on improved efficacy, tolerability and patient convenience. Needle-free, including oral, formulas, expanded indications and combination metabolic approaches have emerged as major priorities across the sector. SureNano Science is positioning itself in this scenario as a nimble participant pursuing differentiated innovation through GEP-44, a patented triple agonist peptide licensed from Syracuse University and designed to advance through the U.S. Food and Drug Administration ("FDA") regulatory route.A Next-Gen Candidate Built for Better OutcomesSureNano Science is developing GEP-44 as a patented next-generation metabolic therapy designed to address the limitations of first-generation GLP-1 drugs, positioning this up-and-coming microcap as a small but strategically focused company moving through the FDA process. Unlike traditional GLP-1 agonists, which act on a single receptor pathway, GEP-44 functions as a triple agonist targeting GLP-1 alongside peptide YY receptors Y1 and Y2. This combined mechanism is designed to simultaneously regulate glucose metabolism, reduce appetite and improve tolerability within a single therapeutic molecule.The compound originated at Syracuse University and has generated promising results in preclinical settings. According to research, GEP-44 produced meaningful reductions in food intake and decreased body weight while also enhancing glycemic control in preclinical models. In addition, the compound did not trigger the nausea, malaise and gastrointestinal adverse effects commonly seen with many first-generation GLP-1 therapies, a distinction that could become increasingly significant as patient populations and adherence demands grow.The broader pharmaceutical industry is investing aggressively in incretin therapies that can address tolerability and long-term adherence challenges. PwC reports that the next segment of the obesity drug market will most likely be characterized by expanded indications, more patient-friendly delivery formats and therapies with stronger adherence profiles. This lends itself to a supportive environment for companies pursuing second-generation GLP innovation.Despite being smaller than more-established pharmaceutical players, SureNano Science operates with a lean development model and cost-efficient structure built for flexibility and development speed. The company is involved in substantial research in Australia, where government incentive programs may provide research tax credits of up to 43.5% on qualifying expenditures. Should GEP-44 continue producing favorable results through clinical development, the company could emerge as an attractive acquisition, licensing or partnership candidate within the fast-expanding GLP ecosystem.Market Scale and the Commercial Case for GLP-1 InnovationThe commercial potential tied to GLP-1 therapies is expanding quickly. According to Morgan Stanley, the global GLP-1 market could reach $190 billion by 2035 as patient adoption broadens and therapeutic applications extend into new disease areas. Industry forecasts from BCC Research also forecast significant long-term growth, with the GLP-1 analogue market estimated to reach $268.4 billion by 2030.Patient uptake estimates that between 25 and 30 million Americans could be using GLP-1 therapies by 2030, up from approximately 10 million in 2026. Increasing insurance coverage along with obesity prevalence and growing physician familiarity are all driving the rapid mainstreaming of these treatments.At the same time, the competitive setting is shifting toward the next wave of products. IQVIA calls 2026 the "year of the orals," with oral GLP-1 formulations projected to meaningfully enhance accessibility, compliance and long-term maintenance therapy adoption. The anticipated off-patent expansion of semaglutide across major global markets is also expected to intensify competition while broadening overall patient access.As GEP-44 advances through IND-enabling studies and moves toward eventual phase 1 trials, SureNano Science stands as one of a small number of microcap public companies offering direct exposure to the expanding GLP-1 market. This positioning may represent a meaningful valuation gap relative to large-cap pharmaceutical incumbents and late-stage obesity therapy developers, particularly if the company achieves key clinical and regulatory milestones.Delivery Innovation as a Second Engine of ValueAlongside its core therapeutic development efforts, SureNano Science is also eyeing differentiated drug-delivery technologies designed to improve patient accessibility and long-term adherence. The company's platform strategy includes evaluating oral, sublingual and intranasal delivery approaches that could eventually reduce reliance on injectable administration.Convenience and adherence have emerged as increasingly important competitive dimensions within the GLP-1 market. The dominant therapies today are injection-based, creating barriers for some patients due to administration complexity, refrigeration requirements and long-term compliance challenges. Noninvasive and oral alternatives are widely regarded as representing one of the most significant near-term commercial opportunities in obesity and diabetes treatment.Industry analysts increasingly view delivery innovation as potentially as consequential as efficacy improvements. IQVIA notes that oral obesity therapies could substantially boost long-term maintenance adoption while simplifying supply chains by removing cold-chain requirements, factors that could meaningfully expand patient access in international markets.By combining therapeutic development with delivery innovation, SureNano Science is working to build a vertically integrated metabolic disease platform rather than advancing a single injectable drug candidate. This broader strategy may generate additional long-term optionality and commercial flexibility as the obesity treatment market continues to evolve.Preclinical Data Point to a Meaningful Competitive EdgePreclinical data from SureNano Science suggest that GEP-44 may offer substantive differentiation relative to earlier-generation GLP therapies. According to the company, the compound demonstrated approximately 15% weight loss in preclinical testing, compared with roughly 9% observed with liraglutide, while food intake reductions reached approximately 39% versus around 20% for the comparator.In addition to weight reduction, GEP-44 produced improvements in glycemic control while reportedly avoiding nausea and vomiting during testing. Gastrointestinal side effects remain among the most frequently cited challenges associated with currently marketed GLP-1 therapies and represent a significant driver of discontinuation. Improved tolerability could therefore become a meaningful competitive advantage if these preclinical findings are validated in human studies.The pharmaceutical industry continues to pour resources into next-generation obesity therapies capable of delivering better outcomes and patient experiences. The Pharma Letter reports that obesity drug pipelines are increasingly oriented toward differentiation through combination receptor pathways, improved tolerability profiles, and expanded delivery options as the competitive field intensifies.While GEP-44 remains in preclinical development, these early findings place SureNano Science within a strategically important segment of the obesity treatment landscape. If subsequent studies continue to support these results, the company could establish itself as a distinctive participant in one of the largest and most rapidly expanding therapeutic categories in contemporary healthcare.Exploring Broader Platform Opportunities for Long-Term GrowthBeyond its primary GLP-1 metabolic platform, SureNano Science is also evaluating early-stage opportunities that could expand the long-term scope of its therapeutic and delivery technology portfolio. These discussions include nonbinding opportunities involving ibogaine-related intellectual property concentrated on formulation and delivery technologies.While still exploratory and not considered a core asset at this stage, the initiative reflects a broader strategic aim of building diversified platform capabilities across multiple high-growth therapeutic areas. Scientific and investor interest in ibogaine and related psychedelic-derived therapeutics has grown considerably in recent years, as researchers examine their potential applications in addiction treatment, mental health conditions, and neurological disorders.CNN recently reported on the growing scientific and regulatory attention being directed at ibogaine research, particularly in areas related to opioid addiction and treatment-resistant mental health conditions. The U.S. Food and Drug Administration has also signaled increasing openness to accelerating development pathways for treatments targeting serious mental illnesses and areas of significant unmet medical need.SureNano's interest in formulation and delivery technologies within these emerging areas fits naturally with the company's broader emphasis on drug-delivery innovation and platform versatility. Rather than treating ibogaine-related opportunities as a standalone commercial priority, the company appears to be assessing how specialized delivery technologies and intellectual property could complement its existing capabilities in metabolic therapeutics and nontraditional administration. This kind of optionality may provide incremental long-term strategic value if the regulatory landscape surrounding psychedelic-based therapies continues to evolve.These initiatives remain early stage and are subject to meaningful scientific, clinical and regulatory uncertainty. However, by selectively evaluating expansion opportunities alongside its primary GLP-1 development program, SureNano Science is aligning itself with a broader trend toward diversified therapeutic platforms capable of competing across multiple large and evolving healthcare markets. As pharmaceutical innovation increasingly converges around metabolic health, neuroscience, and advanced delivery technologies, strategic flexibility may prove to be a growing differentiator for emerging biotechnology companies.Advances Continue Across the GLP-1 LandscapeMomentum across the GLP-1 and metabolic disease sector continues to accelerate as leading biotechnology and pharmaceutical companies expand development programs targeting obesity, diabetes, liver disease and broader cardiometabolic conditions. Recent news from the GLP-1 space highlights continued investment in next-generation therapies, late-stage clinical development, strategic partnerships and regulatory progress as the rapidly evolving space remains one of the most closely watched areas in healthcare and biotechnology.Merck & Co. Inc. (NYSE: MRK) expanded into the GLP-1 and obesity-treatment market through an exclusive global licensing agreement with Hansoh Pharma for an investigational oral GLP-1 receptor agonist. Merck stated that the candidate is being developed for cardiometabolic diseases and described the agreement as part of the company's strategy to strengthen its presence in metabolic disorders. The company noted that it will receive exclusive rights outside China to develop, manufacture and commercialize the therapy, reflecting a growing industry focus on oral GLP-1 treatments for obesity and related conditions.AbbVie Inc. (NYSE: ABBV) announced positive topline results from a phase 1 multiple ascending dose study evaluating ABBV-295, its long-acting amylin analog being developed for obesity and metabolic disease treatment. AbbVie reported that ABBV-295 demonstrated "clinically meaningful" body weight reduction ranging from approximately 7.75% to 9.79% over the treatment period, while also showing a "favorable tolerability profile" with no serious adverse events reported. The company emphasized that the data support continued advancement of its metabolic disease pipeline amid increasing interest in next-generation obesity therapies that may complement or compete with GLP-1 drugs.Viking Therapeutics Inc. (NASDAQ: VKTX) reported completion of enrollment in its phase 3 VANQUISH-2 trial evaluating VK2735, its dual GLP-1/GIP receptor agonist candidate for obesity treatment. Viking stated that the study is assessing subcutaneous VK2735 in adults with obesity and type 2 diabetes, while concurrent phase 3 development is also ongoing in broader obesity populations. The company noted that VK2735 is being developed in both oral and injectable formulations for metabolic disorders, underscoring its position in the rapidly expanding GLP-1 obesity-treatment landscape.Altimmune Inc. (NASDAQ: ALT) announced that pemvidutide received FDA Breakthrough Therapy designation for the treatment of MASH, further advancing development of the company's GLP-1/glucagon dual receptor agonist platform. Altimmune stated that pemvidutide has demonstrated improvements in liver fat reduction, weight loss and fibrosis-related measures, while the company plans to initiate a Phase 3 trial evaluating multiple doses over a 52-week treatment period. The announcement reinforces Altimmune's ongoing efforts to position pemvidutide within the broader GLP-1 and metabolic disease sector spanning obesity, liver disease and related cardiometabolic conditions.Collectively, these developments underscore the growing importance of GLP-1-related therapies as companies compete to address some of the world's largest and fastest-growing chronic health challenges. With ongoing advances in oral formulations, combination therapies and expanded metabolic disease applications, the sector continues to attract significant scientific, clinical and investor attention while reshaping the future landscape of obesity and cardiometabolic treatment.For further information about SureNano Science Ltd., visit the SureNano Science profile.About BioMedWireBioMedWire ("BMW") is a specialized communications platform with a focus on the latest developments in the Biotechnology (BioTech), Biomedical Sciences (BioMed) and Life Sciences sectors. It is one of 75+ brands within the Dynamic Brand Portfolio @ IBN that delivers: (1) access to a vast network of wire solutions via InvestorWire to efficiently and effectively reach a myriad of target markets, demographics and diverse industries; (2) article and editorial syndication to 5,000+ outlets; (3) enhanced press release enhancement to ensure maximum impact; (4) social media distribution via IBN to millions of social media followers; and (5) a full array of tailored corporate communications solutions. With broad reach and a seasoned team of contributing journalists and writers, BMW is uniquely positioned to best serve private and public companies that want to reach a wide audience of investors, influencers, consumers, journalists and the general public. By cutting through the overload of information in today's market, BMW brings its clients unparalleled recognition and brand awareness.BMW is where breaking news, insightful content and actionable information converge.To receive SMS alerts from BioMedWire, "Biotech" to 888-902-4192 (U.S. Mobile Phones Only)For more information, please visit https://www.BioMedWire.comDISCLAIMER: BioMedWire (BMW) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. The commentary, views and opinions expressed in this release by BMW are solely those of BMW. Readers of this Article and content agree that they cannot and will not seek to hold liable BMW for any investment decisions by their readers or subscribers. BMW is a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.The Article and content related to the profiled company represent the personal and subjective views of the Author and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author has not independently verified or otherwise investigated all such information. None of the Author, BMW, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer's filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer's securities, including, but not limited to, the complete loss of your investment.BMW HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. "Forward-looking statements" describe future expectations, plans, results, or strategies and are generally preceded by words such as "may", "future", "plan" or "planned", "will" or "should", "expected," "anticipates", "draft", "eventually" or "projected". You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company's annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and BMW undertakes no obligation to update such statements.Please see full terms of use and disclaimers on the BioMedWire website applicable to all content provided by BMW, wherever published or re-published: https://www.BioMedWire.com/DisclaimerBioMedWire
Austin, Texas
www.BioMedWire.com
512.354.7000 Office
Editor@BioMedWire.comBioMedWire is powered by IBN Original: Next-Generation GLP-1 Innovation Could Unlock Massive Metabolic Healthcare Market Opportunities

Accessible Health Platforms Gain Scale Across $6T Health and Wellness MarketFebruary 13, 2026 11:26 AM
PR Newswire (US)

ISSUED ON BEHALF OF DOSEOLOGY SCIENCES INC.VANCOUVER, BC, Feb. 13, 2026 /PRNewswire/ -- Equity-Insider.com News Commentary – The global health and wellness sector is entering 2026 on a trajectory toward $6 trillion in annual consumer spending, underpinned by rising demand for functional products that deliver measurable outcomes beyond basic nutrition[1]. At the same time, the FDA's updated "Healthy" labeling framework and stricter clean-label regulations are reshaping how brands formulate and position consumer health products, pushing innovation toward sugar-free, preservative-free, and portable delivery systems[2]. Five companies operating along that accessibility curve include Doseology Sciences (CSE: MOOD), Amneal Pharmaceuticals (NASDAQ: AMRX), Prestige Consumer Healthcare (NYSE: PBH), Viking Therapeutics (NASDAQ: VKTX), and Insulet (NASDAQ: PODD).A recent Global Wellness Summit forecast identifies personalized oral delivery and functional reformulation as defining themes for 2026, as consumers prioritize convenience, clinical credibility, and precise dosing[3]. That convergence of wellness innovation and broader healthcare accessibility is channeling capital toward platforms built around scalable, consumer-centric health delivery[4].Doseology Sciences Inc. (CSE: MOOD) (OTCPK: DOSEF) (FSE: VU70) recently launched pilot production of caffeine-based energy pouches in January 2026, marking the Feed That Brain brand's entry into the fast-expanding oral pouch category. Based in Kelowna, British Columbia, Doseology Sciences is producing nicotine-free pouches that deliver measured caffeine doses in a compact, portable format, drawing on the same consumer shift that turned tobacco-free nicotine pouches into a multibillion-dollar segment.The pilot pouches skip the sugar, carbonation, and liquid volume found in conventional energy drinks. A direct-to-consumer test phase is planned to collect customer feedback and operational data ahead of any broader commercial launch."This pilot reflects a disciplined and intentional approach to evaluating new product formats within our platform," said Tim Corkum, President and COO of Doseology Sciences. "Feed That Brain brings a strong foundation in functional product design, and this initiative allows us to assess caffeine-based, pouch-format energy delivery under a measured and compliant framework."The energy pouch program grew out of Doseology Sciences' August 2025 acquisition of the Feed That Brain brand for $400,000, paid entirely through stock issuance. Feed That Brain, a Toronto-based cognitive health label founded by Forbes-recognized entrepreneur Rena R. Dempsey, built its reputation on functional gummies and nootropic supplements designed to support mental performance.Doseology Sciences also secured Joseph Mimran as Strategic Advisor under a three-year agreement valued at $400,000 in restricted share units. Mimran co-founded Alfred Sung, founded Club Monaco (later acquired by Ralph Lauren), and created the Joe Fresh retail brand. He cited the company's product development process and attention to regulatory compliance as reasons for joining.Two large market tailwinds support the strategy. Grand View Research projects the global energy drinks market will grow from $79.4 billion in 2024 to $125.1 billion by 2030. The nicotine pouch segment is forecast to climb from $5.4 billion in 2024 to over $25 billion by 2030, reflecting a 29.6% annual growth rate. Rising consumer concern over sugar intake and beverage overconsumption continues to push demand toward alternative caffeine delivery methods.Doseology Sciences currently distributes Gummies and Collagen products under the Feed That Brain brand across close to 500 Canadian retail locations. Its U.S. subsidiary, Doseology USA Inc., established earlier this year, is working on pouches that blend caffeine with nootropics and adaptogens. The leadership team now includes CEO Chris Jackson, President and COO Tim Corkum, and Strategic Go-to-Market Advisor Patrick Sills.CONTINUED... Read this and more news for Doseology Sciences at:https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/Amneal Pharmaceuticals (NASDAQ: AMRX) introduced a new brand identity reflecting its evolution into a diversified global biopharmaceutical leader, anchored by a refreshed logo symbolizing the trust placed in healthcare providers and the real-world impact of each prescription. The company now delivers more than 160 million prescriptions annually across a portfolio of over 290 medicines."As Amneal has grown and diversified, our brand needed to evolve with us," said Chirag Patel, Co-Founder and Co-CEO of Amneal Pharmaceuticals. "This new brand reflects who we are today and where we are headed. It signals our ambition, our capabilities, and our unwavering focus on expanding access to medicines that make a meaningful difference in people's lives."Amneal Pharmaceuticals plans to introduce its Accessibility Index later this year, a platform designed to demonstrate real impact on affordability, availability, and innovation across its portfolio spanning complex generics, injectables, biosimilars, and specialty therapies.TheraTears, a subsidiary of Prestige Consumer Healthcare (NYSE: PBH), expanded its dry eye portfolio with two new products launching nationwide in February 2026: Eyelid Cleansing Wipes and Dry & Tired Preservative Free Lubricant Eye Drops. The preservative-free drops contain twice the hydrating ingredient of TheraTears' original formula and target consumers experiencing screen-related eye fatigue.The Eyelid Cleansing Wipes are formulated for gentle daily use with a non-stinging formula that removes irritants aggravating dry eye symptoms. Both products will be available at Amazon, Walgreens, and Walmart as part of the ophthalmologist-created brand's growing family of eye care solutions under Prestige Consumer Healthcare.Viking Therapeutics (NASDAQ: VKTX) reported fourth quarter and full-year 2025 financial results highlighting rapid progress across its obesity portfolio, ending the year with $706 million in cash to fund near-term catalysts including Phase 3 VANQUISH trials for subcutaneous VK2735. VANQUISH-1 enrollment exceeded 4,500 patients ahead of schedule, while VANQUISH-2 nears full enrollment."The past year was an exceptional year for Viking marked by rapid progress across our obesity portfolio," said Brian Lian, Ph.D., CEO of Viking Therapeutics. "We also expect to file an IND for our novel amylin agonist this quarter, expanding our obesity franchise."Viking Therapeutics plans to advance oral VK2735 into Phase 3 development in the third quarter of 2026, with maintenance dosing study results also expected in that period. The dual GLP-1/GIP agonist demonstrated up to 14.7% weight loss from baseline in its Phase 2 VENTURE trial.Insulet (NASDAQ: PODD) launched its Omnipod 5 Automated Insulin Delivery System across Saudi Arabia, Kuwait, Qatar, and the United Arab Emirates, bringing the tubeless wearable pump's global availability to 19 countries. The company simultaneously debuted Omnipod Discover, a proprietary data analytics platform designed to simplify glucose and insulin delivery insights for users and healthcare providers."We're proud to bring Omnipod 5 to a region where the unmet need is great," said Pat Crannell, Senior Vice President and International General Manager of Insulet. "It is even more meaningful and impactful with the inaugural introduction of Omnipod Discover, which simplifies data management and helps us create a world where diabetes demands less, every day."Insulet plans to launch Omnipod 5 in Spain later in 2026, followed by Greece and Croatia in the first half of 2027. Omnipod Discover will roll out to additional international markets after the Middle East introduction.Article Source: https://equity-insider.com/2025/12/19/what-comes-after-cigarettes-vapes-and-energy-drinks/ CONTACT:Equity Insider
info @acblanke1DISCLAIMER: Nothing in this publication should be considered as personalized financial advice. We are not licensed under securities laws to address your particular financial situation. No communication by our employees to you should be deemed as personalized financial advice. Please consult a licensed financial advisor before making any investment decision. This is a paid advertisement and is neither an offer nor recommendation to buy or sell any security. We hold no investment licenses and are thus neither licensed nor qualified to provide investment advice. The content in this report or email is not provided to any individual with a view toward their individual circumstances. Equity-Insider.com is a wholly-owned subsidiary of Market IQ Media Group, Inc. ("MIQ"). "). This article is being distributed for Maynard Communications ("MAY"), who has been paid a fee for an advertising campaign. MIQ has not been paid a fee for Doseology Sciences. Inc. advertising or digital media, but expects to be paid a fee from ("MAY"). There may be 3rd parties who may have shares of Doseology Sciences Inc., and may liquidate their shares which could have a negative effect on the price of the stock. This compensation constitutes a conflict of interest as to our ability to remain objective in our communication regarding the profiled company. Because of this conflict, individuals are strongly encouraged to not use this publication as the basis for any investment decision. The owner/operator of MIQ own shares of Doseology Sciences Inc., which were purchased as a part of a private placement. We also expect further compensation as an ongoing digital media effort to increase visibility for the company, no further notice will be given, but let this disclaimer serve as notice that all material, including this article, which is disseminated by MIQ has been approved by Doseology Sciences Inc.; this is a paid advertisement, we currently own shares of Doseology Sciences Inc. and will buy and sell shares of the company in the open market, or through private placements, and/or other investment vehicles. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in our newsletter is not trustworthy unless verified by their own independent research. Also, because events and circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.SOURCES:1. https://www.precedenceresearch.com/functional-beverages-market2. https://www.mordorintelligence.com/industry-reports/global-functional-food-market3. https://globalwellnessinstitute.org/press-room/press-releases/global-wellness-summit-releases-10-wellness-trends-for-2026/4. https://insights.citeline.com/hbw-insight/perspectives/consumer-health-and-wellness-market-outlook-what-trends-will-impact-self-care-in-2026-T7WQJYMDZJE4FLRJAEHVIT7REE/Logo - https://mma.prnewswire.com/media/2840019/5798142/Equity_Insider_Logo.jpg

View original content to download multimedia:https://www.prnewswire.com/news-releases/accessible-health-platforms-gain-scale-across-6t-health-and-wellness-market-302687851.html

Original: Accessible Health Platforms Gain Scale Across $6T Health and Wellness Market